Janux Therapeutics, Inc. is a cutting-edge biopharmaceutical company based in La Jolla, California, that specializes in next-generation immunotherapies for cancer through its proprietary Tumor Activated T Cell Engager (TRACTr) platform. Committed to transforming oncology care, Janux aims to develop highly targeted therapies that improve patient outcomes by effectively targeting and eliminating tumor cells. With a strong foundation in T cell biology and an innovative approach to tumor activation, the company is strategically positioned to meet urgent unmet needs in cancer treatment and advance the field of immuno-oncology. Show more

Location: 10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, UNITED STATES, 92130, San Diego, CA, 92130, USA | Website: https://www.januxrx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

801.8M

52 Wk Range

$12.12 - $41.56

Previous Close

$13.33

Open

$13.20

Volume

1,522,300

Day Range

$12.12 - $13.36

Enterprise Value

-164.6M

Cash

48.39M

Avg Qtr Burn

-12.86M

Insider Ownership

6.91%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
JANX007 (PSMA-TRACTr) Details Castration-resistant prostate cancer (mCRPC)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JANX008 (EGFR-TRACTr) Details Cancer, advanced or metastatic solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.